AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31872552 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH) treatment, specific dosage and duration not mentioned.
Number of subjects: 0
Study 31872552 — intervention group
Group type: COMPARATOR
Intervention: Classical endocrinological approach (substitutive regimen for hypogonadotropic hypogonadism), specific details not mentioned.
Number of subjects: 0
Study 30182858 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 5-10 mg TID
Number of subjects: 0
Study 30182858 — intervention group
Group type: EXPERIMENTAL
Intervention: acetyl-DL-leucine
Number of subjects: 0
Study 30182858 — intervention group
Group type: COMPARATOR
Intervention: sustained-release (SR) form of 4-AP
Number of subjects: 0
Study 30182858 — intervention group
Group type: COMPARATOR
Intervention: SR form of 4-AP
Number of subjects: 0
Study 28062251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (0.7ng/ml target-controlled infusion)
Number of subjects: 0
Study 28062251 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 25613351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) DBS + Optimal Drug Therapy (ODT)
Number of subjects: 30
Study 25613351 — intervention group
Group type: COMPARATOR
Intervention: Optimal Drug Therapy (ODT)
Number of subjects: 30
Study 23083831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone intravaginal suppository
Number of subjects: 0
Study 23083831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21457679 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus brief behavioral therapy for insomnia (4 weekly 1-hour sessions)
Number of subjects: 37
Study 21457679 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 37
Study 19269744 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic noxious conditioning stimulation (HNCS)
Number of subjects: 10
Study 19269744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 17350395 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Telepresence (RTP)
Number of subjects: 0
Study 15076931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal practices (including wiping, douching, or inserting substances into the vagina)
Number of subjects: 2897
Study 11339068 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual method of RBC collection
Number of subjects: 5
Study 11339068 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis procedure of RBC collection
Number of subjects: 5
Study 9476458 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (single dose)
Number of subjects: 176
Study 9476458 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin (7-day regimen)
Number of subjects: 176
Study 7944693 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted techniques
Number of subjects: 67
Study 7944693 — intervention group
Group type: COMPARATOR
Intervention: Muscle-sparing procedures
Number of subjects: 67
Study 3410630 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week progressive strength training
Number of subjects: 21
Study 29717075 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based discussion after lecture
Number of subjects: 52
Study 29717075 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based discussion before lecture
Number of subjects: 52
Study 29717075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case-based discussion)
Number of subjects: 52
Study 28245726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg orally each night for 28 days
Number of subjects: 18
Study 28245726 — intervention group
Group type: COMPARATOR
Intervention: Placebo each night for 28 days
Number of subjects: 18
Study 26303750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil analgesia
Number of subjects: 140
Study 26303750 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 140
Study 26303750 — intervention group
Group type: COMPARATOR
Intervention: Control (no analgesia)
Number of subjects: 140
Study 23354164 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided in-plain injection
Number of subjects: 126
Study 23354164 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided out-of-plain injection
Number of subjects: 126
Study 23354164 — intervention group
Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 126
Study 21750097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided approach
Number of subjects: 141
Study 21750097 — intervention group
Group type: COMPARATOR
Intervention: Blind approach
Number of subjects: 141
Study 18286488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation without planned neck dissection
Number of subjects: 102
Study 16096781 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cue-target interval (200 ms)
Number of subjects: 15
Study 16096781 — intervention group
Group type: EXPERIMENTAL
Intervention: Long cue-target interval (2000 ms)
Number of subjects: 15
Study 16096781 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable trial sequence
Number of subjects: 15
Study 16096781 — intervention group
Group type: EXPERIMENTAL
Intervention: Short preparatory intervals
Number of subjects: 15
Study 12748343 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 36
Study 12748343 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 36
Study 11090750 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche AMPLICOR EV test (PCR)
Number of subjects: 465
Study 11090750 — intervention group
Group type: COMPARATOR
Intervention: Culture
Number of subjects: 465
Study 8796234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 10 cmH2O
Number of subjects: 10
Study 8796234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 20 cmH2O
Number of subjects: 10
Study 8796234 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory pressure of 0 cmH2O
Number of subjects: 10
Study 1518731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800 mg/day for 6 days
Number of subjects: 1
Study 1518731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 6381018 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 0
Study 6381018 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 0
Study 6381018 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 0
Study 30722001 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 μg)
Number of subjects: 36
Study 30722001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL 0.9% saline)
Number of subjects: 36
Study 29777632 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF) plus Connective Tissue Graft (CTG)
Number of subjects: 25
Study 29777632 — intervention group
Group type: COMPARATOR
Intervention: Coronally Advanced Flap (CAF) alone
Number of subjects: 25
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC bleeding (grades 2, 3, or 5)
Number of subjects: 12944
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI minor/major bleeding
Number of subjects: 12944
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: GUSTO moderate/severe bleeding
Number of subjects: 12944
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG-related bleeding (BARC 4)
Number of subjects: 12944
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC (2, 3, or 4) bleeding
Number of subjects: 12944
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC 4 bleeding
Number of subjects: 12944
Study 27151345 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of BARC (2, 3, or 4) bleeding in the 1-year mortality model
Number of subjects: 12944
Study 24885789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound real-time guidance and examination
Number of subjects: 300
Study 24885789 — intervention group
Group type: COMPARATOR
Intervention: Landmark guidance and radiographic examination
Number of subjects: 300
Study 22280352 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg/die of vitamin K (G I)
Number of subjects: 53
Study 22280352 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 μg/die of vitamin K (G II)
Number of subjects: 53
Study 22280352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (G III)
Number of subjects: 53
Study 20164823 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (high-dose); administered based on biomarker levels above 46.3
Number of subjects: 529
Study 20164823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 18757324 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight patients (BMI, 21 to 24.9 kg/m(2))
Number of subjects: 1053
Study 18757324 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II to III obesity (BMI >or= 35 kg/m(2))
Number of subjects: 1053
Study 18757324 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change during adjuvant therapy
Number of subjects: 1053
Study 15977316 — intervention group
Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 0
Study 15977316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15977316 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in open label
Number of subjects: 0
Study 12765749 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 12
Study 12765749 — intervention group
Group type: COMPARATOR
Intervention: Saccharin
Number of subjects: 12
Study 9808821 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief proactive educational intervention over the telephone with two follow-up mailouts, based on NCI 5 A Day for Better Health program.
Number of subjects: 1672
Study 7612098 — intervention group
Group type: EXPERIMENTAL
Intervention: Leboyer childbirth (cord clamping after 3 minutes)
Number of subjects: 30
Study 7612098 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (less than 10 seconds)
Number of subjects: 30
Study 7612098 — intervention group
Group type: EXPERIMENTAL
Intervention: Leboyer childbirth and Early cord clamping
Number of subjects: 30
Study 2142949 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) - 50 micrograms bolus, then 1 microgram/min infusion
Number of subjects: 20
Study 2142949 — intervention group
Group type: COMPARATOR
Intervention: Mannitol - 15% at 100 ml/hr
Number of subjects: 20
Study 301743 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (CABG)
Number of subjects: 57
Study 301743 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 57
Study 29855281 — intervention group
Group type: EXPERIMENTAL
Intervention: TAO, an internet-based program for AjD composed of seven modules combining CBT and Positive Psychology strategies, with short weekly telephone support.
Number of subjects: 0
Study 29855281 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group, assessed before and after a seven-week waiting period.
Number of subjects: 0
Study 29855281 — intervention group
Group type: EXPERIMENTAL
Intervention: TAO intervention measured using BDI-II and BAI as primary outcome measures.
Number of subjects: 0
Study 28371189 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test (GST) with 1 mg i.v. glucagon
Number of subjects: 10
Study 28371189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT) with a liquid mixed meal
Number of subjects: 10
Study 28371189 — intervention group
Group type: COMPARATOR
Intervention: Correlation between GST and MMTT C‐peptide levels
Number of subjects: 10
Study 28371189 — intervention group
Group type: EXPERIMENTAL
Intervention: MMTT GIP and C‐peptide levels
Number of subjects: 10
Study 26247145 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled, color-coded syringes
Number of subjects: 10
Study 26247145 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication administration
Number of subjects: 10
Study 23911734 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous microwave ablation (EMA)
Number of subjects: 0
Study 23911734 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping (HLS)
Number of subjects: 0
Study 21426749 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 individuals without CAD)
Number of subjects: 120
Study 21426749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina pectoris (SA) group (30 patients)
Number of subjects: 120
Study 21426749 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable angina pectoris/non-ST-segment elevation myocardial infarction (UA/NSTEMI) group (30 patients)
Number of subjects: 120
Study 21426749 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation myocardial infarction (STEMI) group (30 patients)
Number of subjects: 120
Study 21426749 — intervention group
Group type: EXPERIMENTAL
Intervention: Local levels in UA/NSTEMI group
Number of subjects: 120
Study 21426749 — intervention group
Group type: EXPERIMENTAL
Intervention: Local levels in STEMI group
Number of subjects: 120
Study 21426749 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus levels in STEMI patients
Number of subjects: 120
Study 18344730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d escitalopram
Number of subjects: 151
Study 18344730 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d escitalopram
Number of subjects: 151
Study 18344730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 17089111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 2.4 mg/kg body weight
Number of subjects: 17
Study 14554068 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoconnect (CC) (Heraus Kulzer)
Number of subjects: 8
Study 14554068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Repair (CF) (Kuraray)
Number of subjects: 8
Study 14554068 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐purpose adhesive resin (MP) (3M‐ESPE)
Number of subjects: 8
Study 14554068 — intervention group
Group type: COMPARATOR
Intervention: Control (no surface treatment)
Number of subjects: 8
Study 11574766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with nitrosoureas
Number of subjects: 0
Study 11574766 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive and palliative care including neurorehabilitation
Number of subjects: 0
Study 9635475 — intervention group
Group type: EXPERIMENTAL
Intervention: Down's syndrome patients with DAT
Number of subjects: 106
Study 9635475 — intervention group
Group type: COMPARATOR
Intervention: Nondemented Down's syndrome patients
Number of subjects: 106
Study 9635475 — intervention group
Group type: COMPARATOR
Intervention: Japanese nondemented controls
Number of subjects: 106
Study 9635475 — intervention group
Group type: EXPERIMENTAL
Intervention: Down's syndrome patients with DAT under 50 years
Number of subjects: 106
Study 7810189 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol
Number of subjects: 0
Study 7810189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose estradiol
Number of subjects: 0
Study 7810189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3047339 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin, cyclophosphamide, methotrexate)
Number of subjects: 88
Study 3047339 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of doxorubicin and cyclophosphamide without methotrexate
Number of subjects: 88
Study 3047339 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 88
Study 1448121 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim once daily)
Number of subjects: 310
Study 1448121 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg administered every four weeks by jet nebulizer)
Number of subjects: 310
Study 1448121 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 310
Study 1448121 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine
Number of subjects: 310
Study 756475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent positive reinforcement procedure emphasizing moderation
Number of subjects: 0
Study 756475 — intervention group
Group type: COMPARATOR
Intervention: Traditional denial-confrontation therapy emphasizing abstinence
Number of subjects: 0
Study 31856618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study 31856618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31825027 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT+PN
Number of subjects: 90
Study 31825027 — intervention group
Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 90
Study 31825027 — intervention group
Group type: COMPARATOR
Intervention: PN
Number of subjects: 90
Study 28283018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg)
Number of subjects: 77
Study 28283018 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (1 μg/kg)
Number of subjects: 77
Study 25723884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus DEX (800 mg/m DEX 30 minutes before epirubicin administration)
Number of subjects: 80
Study 25723884 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo 30 minutes before epirubicin administration)
Number of subjects: 80
Study 25232512 — intervention group
Group type: EXPERIMENTAL
Intervention: RV transdermal patch (RV-TDP)
Number of subjects: 20
Study 25232512 — intervention group
Group type: COMPARATOR
Intervention: RV capsules (RV-CP)
Number of subjects: 20
Study 22605639 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mammographic screening (active study population)
Number of subjects: 57171
Study 22605639 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive study population)
Number of subjects: 57171
Study 20004330 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (2 mg/day)
Number of subjects: 120
Study 20004330 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4 mg/day)
Number of subjects: 120
Study 20004330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20004330 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3 ng/mL or less)
Number of subjects: 120
Study 20004330 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 120
Study 17225920 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid addition (60 mg/portion) in product B
Number of subjects: 42
Study 17225920 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase treatment in product C
Number of subjects: 42
Study 17225920 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of citric acid addition, dephytinization, and iron supplementation
Number of subjects: 42
Study 15455740 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical subgingival application of hyaluronic acid gel
Number of subjects: 20
Study 15455740 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study 11743622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 1% pilocarpine solution
Number of subjects: 40
Study 11743622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 2% pilocarpine solution
Number of subjects: 40
Study 11743622 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 40
Study 9845139 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + Aprotinin
Number of subjects: 119
Study 9845139 — intervention group
Group type: COMPARATOR
Intervention: placebo + Aprotinin
Number of subjects: 119
Study 9845139 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 119
Study 7986790 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (5 mg) on 5 days every week for 1 year
Number of subjects: 90
Study 7986790 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (Protovit) plus FeSO4 (200 mg once weekly) on 5 days every week for 1 year
Number of subjects: 90
Study 7986790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose) tablet
Number of subjects: 90
Study 7986790 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin and Multivitamin groups (combined)
Number of subjects: 90
Study 2686429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus azlocillin (regimen 1)
Number of subjects: 71
Study 2686429 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin (regimen 2)
Number of subjects: 71
Study 2686429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin followed by oral ciprofloxacin (regimen 3)
Number of subjects: 71
Study 5774314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined triple antigen vaccines with aluminium hydroxide
Number of subjects: 0
Study 5774314 — intervention group
Group type: COMPARATOR
Intervention: Combined triple antigen vaccines without aluminium hydroxide (implied control)
Number of subjects: 0
Study 31173645 — intervention group
Group type: EXPERIMENTAL
Intervention: quizartinib + ketoconazole
Number of subjects: 93
Study 31173645 — intervention group
Group type: EXPERIMENTAL
Intervention: quizartinib + fluconazole
Number of subjects: 93
Study 31173645 — intervention group
Group type: COMPARATOR
Intervention: quizartinib alone
Number of subjects: 93
Study 27178843 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Number of subjects: 56
Study 27178843 — intervention group
Group type: COMPARATOR
Intervention: Pilates
Number of subjects: 56
Study 25758448 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Care Model (SCM)
Number of subjects: 97
Study 25758448 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 97
Study 23816526 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel and prednisone
Number of subjects: 220
Study 23816526 — intervention group
Group type: COMPARATOR
Intervention: docetaxel and prednisone ± AT101
Number of subjects: 220
Study 21316913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stryker Full Navigation
Number of subjects: 40